Abstract: This study uses large deformation medical image registration to analyze, in a disease-specific normalized space, the annual rate of gray matter atrophy caused by frontotemporal dementia (FTD) and its correlation with cognitive decline. The analysis consists of three parts. First, a labeled structural MRI atlas is deformed into the shape of an average FTD brain. Second, annualized FTD-related atrophy of gray matter structures is estimated for each patient in the database. Third, the group-wise annualized atrophy rate caused by FTD is correlated, for each gray matter voxel, with declining performance on cognitive tests. This study gives insight into the relationship between FTD-related progressive cortical atrophy and loss in cognitive function.
F
rontotemporal dementia (FTD) prevalence may be higher than previously thought and may rival Alzheimer disease (AD) in individuals younger than 65 years. 1, 2 Because FTD can be difficult to diagnose clinically, it is important to identify an objective method to support a clinical diagnosis. MRI studies of individual patients are difficult to interpret because of the wide range of acceptable, age-related atrophy in an older cohort susceptible to dementia. This has prompted longitudinal MRI studies that look at both the rate and the anatomic distribution of change.
Longitudinal neuroimaging studies are important not only for early diagnosis, but also for estimating disease stages, targeting disease therapy, and studying treatment progress. To our knowledge, only one longitudinal neuroimaging study of FTD has been performed. 3 The authors partitioned the brain into four quadrants and showed that atrophy in FTD was locally focused and heterogeneous in comparison with AD. By comparison, several studies of longitudinal neuroimaging in AD have been reported. Fox used deformable image registration to map the annual regional atrophy caused by AD 4 and to uncover presymptomatic changes in the medial temporal lobes. Scahill used statistical parametric mapping (SPM) to detail AD atrophy, 5, 6 which was found to affect the hippocampus before clinical signs of AD appeared. Voxel compression mapping found early involvement of the posterior cingulate, temporoparietal cortex, and medial temporal lobes. 4 Jack 7 showed that serial MRI-derived annual atrophy was more statistically powerful than cognitive tests for tracking AD progress. Our methods expand on this work by correlating longitudinal gray matter loss and cognitive test decline, voxelwise, on a disease-specific FTD atlas.
METHODS

Subject Population
The dataset contains eight subjects in total, imaged at two time points each. The average age was 55, with the youngest patient at age 49 and the oldest at 71. The minimum time separation was 0.83 years and the maximum time separation was 3.55 years. The high-resolution T1 structural data (voxel dimensions 0.85 3 0.85 3 1 mm) for each patient originated from a GE Horizon Echospeed 1.5 T MRI scanner (GE Medical Systems, Milwaukee, WI).
Behavioral Tests
All of these subjects performed several cognitive tasks to assess their mental ability at the time of imaging. Three of these tests are analyzed here. The first test is the ''Boston Naming Test'' (BNT) in which the subject names an object from a line drawing. The subject also completed a verbal category membership judgment task (Word). The subject was shown a word and judged whether it was a member of a target category (target categories included ''tools'' and ''vegetables''). The final test involved semantically guided category naming fluency, requiring the subject to name as many ''animals'' as possible in one minute. To obtain a linear estimate of the annualized rate of cognitive decline, we measured the difference between the raw cognitive test scores at time one and time two and divided this by the time interval.
Diffeomorphic Morphometry
Morphometric analysis is performed in a specific coordinate system. A least-biased coordinate system for FTD requires finding a large deformation mean shape of our FTD population. To achieve this, we initially warp all images to an atlas with gray matter segmentation and anatomic labels. 8 This atlas is then deformed iteratively into the average anatomic 
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position to find an optimal shape atlas. 9 This is equivalent to a ''local'' or disease-specific atlas.
Our second goal is to estimate intra-subject annual change in cortical anatomy caused by FTD. Diffeomorphic image registration 9 permits us to deform the later time point structural MRI of each patient, referred to as the ''older'' image, into the shape at the earlier time point, referred to as the ''younger'' image. This physically based registration gives the structural change on a voxel-by-voxel basis, as shown in step one of Figure 1 . The deformation field is then scaled in size by the imaging time interval, in years, giving a linear model of the annualized atrophy occurring in the patient's cortex.
Finally, the annualized structural atrophy map is warped into the FTD atlas space where it may be evaluated statistically. This involves diffeomorphically registering the ''younger'' image and the atlas, and then warping the atrophy map into the atlas space, as in step two of Figure 1 . Repeating this for each patient allows us to compute an average atrophy and expansion map and to correlate structural data with gray matter atrophy. We use Kendall s tau correlation.
RESULTS
Results of the initial intra-subject diffeomorphic method for assessing temporal change are illustrated for one patient in Figure 1 . The alignment of the annualized data to the atlas space is shown in Figure 1 step two, along with the gray matter mask. The average of the annualized atrophy/expansion maps is overlaid on the atlas in Figure 2 . These are thresholded to show average changes in excess of 3%. Frontal and temporal cortical regions show considerable annualized atrophy, while ventricular regions undergo annualized expansion that is most evident anteriorly. The correlations between annualized cortical atrophy and annualized cognitive decline in the FTD atlas MRI are displayed in Figure 3 . The correlations are computed only in gray matter regions that undergo annualized atrophy greater than 3%. Significant correlations are shown (P , 0.05). Prominent correlations are evident in frontal and temporal regions, particularly in the left hemisphere.
DISCUSSION
Our results show considerable longitudinal change in FTD brains. The focus of atrophy is in temporal and frontal lobes, consistent with histopathological studies demonstrating the bulk of disease burden in these brain regions, but atrophy is also seen in the parietal lobes. The atrophy in our dataset is not symmetric with respect to the right and left temporal lobes: it is more prominent on the left, as revealed in Figure 2 . This may reflect that several of the participating patients have progressive aphasia.
Correlations of progressive cortical atrophy with declining performance on cognitive measures associated semantic decisions on the verbal category membership judgment task with frontal and lateral temporal atrophy, particularly on the left. Progressive difficulty retrieving the name of an object on FIGURE 1. The workflow for our study applies a spatial normalization process to each patient. Spatial normalization allows the longitudinal change in gray matter to be correlated with declining cognitive tests on a high-resolution voxel-by-voxel basis.
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q 2005 Lippincott Williams & Wilkins the Boston Naming Test was associated instead with ventral temporal cortical atrophy, again predominantly on the left. Semantically guided category naming fluency involves both semantic decisions and name retrieval, and declining performance on this task reveals multiple frontal and temporal correlations. Quantifying the relationship between cognitive function and structural atrophy such as these will elucidate the effect of focal neurodegeneration on cognitive ability as a function of time, aid interpretation of cognitive tests in anatomic-functional terms, improve diagnostic accuracy, and provide an important yardstick for measuring efficacy in future medication trials. 
